NASDAQ:BCRX
Biocryst Pharmaceuticals Inc.
Biocryst Pharmaceuticals Inc.'s revenue grew 94.1% in fiscal 2025 to $874.8M while operating margin rose to 39.0%, its highest in 10 years. Free cash flow was $344.9M, 39.4% of revenue, and the diluted share count rose 5.7%.Summary generated from Biocryst Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$874.8M
Revenue growth+94.1%
Revenue, 5-yr CAGR+117.9%
Gross margin97.8%
Operating margin39.0%
Net margin30.2%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow$344.9M
FCF margin39.4%
Share count change+5.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 157 | 271 | 331 | 451 | 875 |
| Operating income | −178 | −148 | −104 | −3 | 341 |
| Net income | −184 | −247 | −227 | −89 | 264 |
| Free cash flow | −145 | −163 | −97 | −53 | 345 |
Recent filings
- 4Insider transaction report
Sep 2, 2026 - 4Insider transaction report
Sep 2, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 5, 2026 - 8-K/AAmended costs of exit or disposal activities
Aug 4, 2026 - 8-KCosts of exit or disposal activities
Jun 29, 2026 - 8-KDirector or officer change
Jun 12, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 6, 2026